source
- Tyra Biosciences reports Phase 2 success in low-risk bladder cancer, plans pivotal trialTyra Biosciences announced that its experimental therapy for low‑risk bladder cancer has produced encouraging results in a Phase 2 study. The company said the data, released on Wednesday, represen…
- Caspian Therapeutics launches with $50M funding and Eli Lilly backing to develop menin inhibitor for diabetesCaspian Therapeutics has been created as a spin-out from Kura Oncology to advance a menin-targeting drug for diabetes. The company received $50 million in initial capital, led by BVF Partners with…